Randomized crossover trial to assess the effects and quality of life in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel. QOLINPAC

EudraCT # 2013-004101-75, NCT02106884

DEATHS WHILE ON TREATMENT AND WITHIN 30 DAYS FROM LAST TREATMENT¹

Patient ID	Arm (ITT)	Regimen before death	Gender	Interval on study (days)	Reason for end of treatment	Interval from last treatment to death (days)	Cause of death
01-003	ARM B - G	Gem monotherapy	Female	21	Other/patient refused or withdrew consent	18	Basic disease/Progression
01-010	ARM A - n-P + G	n-P+Gem 1st line	Female	32	Major toxicity according to protocol	27	Basic disease/Progression
02-001	ARM B - G	Gem monotherapy	Male	60	Disease progression	25	Euthanasia
02-002	ARM A - n-P + G	n-P+Gem 1st line	Female	54	Other/patient refused or withdrew consent	11	Basic disease/Progression
02-006	ARM B - G	n-P+Gem 2 nd line	Female	189	Disease progression	30	Euthanasia
04-005	ARM B - G	Gem monotherapy	Male	88	NA/Death	11	Other/Cardiovascular event Unrelated to Gem
05-004	ARM A - n-P + G	n-P+Gem 1st line	Male	176	Disease progression	26	Basic disease/Progression
06-004	ARM B - G	Gem monotherapy	Female	26	NA/Death	6	Other/Sepsis or septic shock Possibly related to Gem
09-001	ARM B - G	Gem monotherapy	Male	101	NA/Death	7	Other/Cardiovascular event Unrelated to Gem
11-002	ARM A - n-P + G	n-P+Gem 1 st line	Female	128	NA/Death	10	Other/Cardiovascular event Unrelated to Abraxane and Gem
11-021	ARM B - G	Gem monotherapy	Male	16	Major toxicity according to protocol	25	Basic disease/Progression
12-009	ARM A - n-P + G	n-P+Gem 1 st line	Male	239	Disease progression	15	Basic disease/Progression
12-011	ARM B - G	n-P+Gem 2 nd line	Male	324	Disease progression	26	Basic disease/Progression
14-001	ARM B - G	Gem monotherapy	Male	57	NA/Death	8	Euthanasia
17-002	ARM B - G	n-P+Gem 2 nd line	Female	84	NA/Death	10	Other/Sepsis or septic shock Unrelated to n-P and Gem
18-002	ARM B - G	n-P+Gem 2 nd line	Female	80	Disease progression	11	Basic disease/Progression

¹ Either Gemcitabine, nab-Paclitaxel or both, as given at last infusion.